Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133274 | 1.00 | TPMT (0.49) | TPMTHCAR2CHEK1NTRK2POLB | |
| SCHEMBL15417931 | 0.86 | HDAC3 (0.41) | TPMTMAPK1HDAC3HDAC1HDAC2 | |
| SCHEMBL13574510 | 0.84 | HDAC3 (0.40) | TPMTCHEK1NTRK2KDM4EMAPK1 | |
| SCHEMBL1505698 | 0.84 | MAPK1 (0.50) | TPMTPOLBKDM4EMAPK1L3MBTL1 | |
| SCHEMBL29130953 | 0.84 | TSHR (0.50) | HDAC3HDAC1HDAC2HDAC6KMT2A | |
| SCHEMBL899216 | 0.83 | MAPT (0.50) | TPMTHCAR2POLBTTRMAPK1 | |
| SCHEMBL443075 | 0.82 | HCAR3 (0.43) | TPMTHCAR2POLBTTRKDM4E | |
| SCHEMBL1963196 | 0.81 | KMT2A (0.42) | TPMTHCAR2POLBTTRP4HA1 | |
| SCHEMBL16113447 | 0.80 | KMT2A (0.45) | HCAR2POLBTTRL3MBTL1KMT2A | |
| SCHEMBL7358042 | 0.80 | PTGS2 (0.50) | TPMTHCAR2POLBKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4643949-A2 | NICOTINAMIDE RIPK1 INHIBITORS | AbbVie Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240360099-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117777099-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-8618304-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| WO-2012124775-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
| EP-2496556-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011053948-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-05-05 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | TPMT 58/4885HCAR2 1047/4885CHEK1 3477/4885 |
| US-20240360099-A1 | NICOTINAMIDE RIPK1 INHIBITORS | RIPK1, RIPK2, RIPK4 | TPMT 317/4885HCAR2 464/4885CHEK1 1295/4885 |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | TPMT 4767/4885HCAR2 24/4885CHEK1 4852/4885 |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | TPMT 3471/4885HCAR2 4848/4885CHEK1 78/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | TPMT 3471/4885HCAR2 4848/4885CHEK1 78/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | TPMT 3396/4885HCAR2 4846/4885CHEK1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.